NCT04669171 - A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 5, 2021

Primary Completion Date

May 30, 2026

Study Completion Date

May 30, 2032

Conditions

Follicular LymphomaMarginal Zone Lymphoma

Interventions

BIOLOGICAL

EO2463

Multiple dose of EO2463

DRUG

lenalidomide

D1-21 of 4-weekly cycles

BIOLOGICAL

rituximab

Multiple doses of rituximab

Trial Locations (12)

14642

RECRUITING

University of Rochester Medical Center (URMC) - Wilmot Cancer Institute (WCI) (James P. Wilmot Cancer Center), Rochester

55905

RECRUITING

Mayo Clinic, Rochester

98109

RECRUITING

University of Washington-Seattle Cancer Care Alliance, Seattle

02215

RECRUITING

Dana Farber Cancer Institute, Boston

Unknown

RECRUITING

CHU d'Amiens-Picardie - Hopital SUD, Amiens

RECRUITING

University of Bologna, Bologna

RECRUITING

IRCCS Policlinico San Matteo Foundation - University of Pavia, Naples

RECRUITING

IRCCS Policlinico San Matteo Foundation - University of Pavia, Pavia

RECRUITING

University Hospital Vall d'Hebron, Institute of Oncology, Barcelona

RECRUITING

Clinica Universidad de Navarra, Madrid

RECRUITING

Clinica Universidad de Navarra, Pamplona

RECRUITING

Hospital Clinico Universitario de Salamanca, Salamanca